The National Institute of Allergy and Infectious Diseases (NIAID) has announced that it will halt its HVTN 505 HIV vaccine
trial due to a perceived lack of efficacy. A scheduled review by an independent data and safety monitoring board found that the vaccine regimen neither prevented HIV infection nor reduced viral load in vaccine recipients who became infected with HIV.
The announcement will come as a blow to those hoping the HVTN 505 would be an effective intervention to stem the HIV pandemic.
HIV particle graphic by Russell Kightley Media